Chả cá Lã Vọng

Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board

Retrieved on: 
星期一, 三月 6, 2023
SITC, MD, ASCO, INSERM, Science, SAN, FITC, Stanford University, Immunology, Chả cá Lã Vọng, Regulatory T cell, École normale supérieure (Paris), Tumor microenvironment, TME, ESMO, Society, University, Entrepreneurship, Doctor of Philosophy, Safety, Professor, AACR, Pharmaceutical industry

SAN DIEGO and SUZHOU, China, March 05, 2023 (GLOBE NEWSWIRE) --  Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Professor Aurélien Marabelle, MD, PhD, to its Scientific and Strategic Advisory Board (the “SAB”). Professor Marabelle is a physician-scientist with expertise in oncology and immunology. His clinical practice is dedicated to early phase clinical trials of cancer immunotherapies with strong translational evidence within the Drug Development Department (DITEP) of Gustave Roussy Cancer Center in France. He leads a translational research laboratory (LRTI) within the INSERM U1015 with a focus on mechanisms of action of immune targeted therapies.

Key Points: 
  • SAN DIEGO and SUZHOU, China, March 05, 2023 (GLOBE NEWSWIRE) --  Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Professor Aurélien Marabelle, MD, PhD, to its Scientific and Strategic Advisory Board (the “SAB”).
  • Professor Marabelle is a physician-scientist with expertise in oncology and immunology.
  • He leads a translational research laboratory (LRTI) within the INSERM U1015 with a focus on mechanisms of action of immune targeted therapies.
  • “Professor Aurélien Marabelle pioneered the intratumoral delivery of anti-CTLA-4 therapy in clinic as a way to overcome the safety issues of anti-CTLA-4 therapy delivered systemically.